Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Level 5 - mechanism / opinion, no new human data
Narrative review of disease mechanisms and proposed therapeutic targets with no original human clinical data.
PubMed 33001359 · doi:10.1007/s10741-020-10031-3
What was done
This narrative review summarizes the pathophysiology of Barth syndrome cardiomyopathy, focusing on TAZ gene defects, cardiolipin deficiency, and impaired ATP generation, while examining the mechanistic basis for treatment with elamipretide.
What was found
The abstract reports that Barth syndrome has an incidence of 1 in 300,000 to 400,000 live births and tafazzin deficiency causes up to a 95% reduction in mature cardiolipin levels. It lists associated phenotypes including dilated cardiomyopathy, left ventricular noncompaction, endocardial fibroelastosis, and hypertrophic cardiomyopathy. It describes elamipretide as associating with cardiolipin on the inner mitochondrial membrane to enhance ATP synthesis, but provides no quantitative clinical trial data or numbers.
Why it matters
It outlines a potential disease-modifying therapeutic mechanism for a lethal genetic mitochondrial cardiomyopathy currently limited to symptomatic management.
Limits
The abstract contains no original clinical trial data, sample sizes, or quantitative outcome metrics for elamipretide, leaving clinical efficacy, safety, and durability unmeasured.
Cited by
- contradicts The brain has the highest density of mitochondria of any organ in the body.